| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health |
2004-002526-22: Estudio para evaluar la eficacia y seguridad de Imiquimod en pacientes con hemangioma infantil |
|
|
| Ongoing | 4 | 20 | Europe | ALDARA, Cream, ALDARA | Instituto Científico y Tecnológico de Navarra, S.A., 3M España, S.A. | Hemangioma Infantil, Tumor vascular benigno caracterizado por un rápido crecimiento durante el primer año de vida, seguido de un periodo de involución que alcanza un grado variable y que dura varios años, Diseases [C] - Cancer [C04] | | | | |
2013-001260-34: Imiquimod treatment of premalignant lesions of the uterine cervix. |
|
|
| Ongoing | 4 | 210 | Europe | Aldara, Cream, Aldara | Maastricht University Medical Center, Maastricht University Medical Center | High grade cervical intraepithelial neoplasia. Hooggradige cervicale intraepitheliale neoplasie., Premalignant lesions of the uterine cervix. Premaligne afwijkingen van de baarmoedermond., Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2004-001262-40: Tratamiento de los hemangiomas de la infancia con imiquimod tópico al 5% |
|
|
| Ongoing | 4 | 58 | Europe | Aldara, 722710, Aldara, Aldara | Investigador del estudio: Dr. Agustín Alomar Muntañola | Hemangiomas de la infancia | | | | |
2007-006761-32: Vulval intraepithelial neoplasia: immune responses to human papillpmavirus. |
|
|
| Ongoing | 4 | 45 | Europe | Aldara 5% cream, Aldara 5% cream | Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | Vulval intraepithelial neoplasia | | | | |
2007-006277-92: Treatment of anal intraepithelial neoplasia in HIV-positive patients, a triple-arm randomized clinical trial |
|
|
| Ongoing | 4 | 150 | Europe | Imiquimod, Fluorouracil, Aldara, Efudix, Aldara, Efudix | Academic Medical Center, department of infectious diseases | anal intraepithealial neoplasia in HIV-positive patients | | | | |
| Ongoing | 4 | 40 | Europe | Imiquimod, N/A, Aldara 5% Cream, Aldara 5% Cream | University Hospitals Birmingham NHS Foundation Trust | lentigo maligna | | | | |
2013-000092-33: PDT versus PDT in combination with 5% Imiquimod in patients with non melanoma skin cancer PDT versus PDT in Kombination mit 5% Imiquimod bei Patienten mit nicht melanozytärem Hautkrebs |
|
|
| Ongoing | 4 | 118 | Europe | 5-Aminolevilinic Acid, Aldara, 5-ALA, Aldara, Aldara | Medizinische Universität Wien, Univ.Klinik.f.Dermatologie, Medizinische Universität Wien, Univ. Klinik für Dermatologie | non melanoma skin cancer nicht melanozytäre Hauttumore | | | | |
2013-004037-32: Study of two diagnostic tools in lesion count during treatment Estudio de dos técnicas diagnósticas para el recuento de lesiones durante el tratamiento |
|
|
| Ongoing | 4 | 20 | Europe | zyclara, ZYCLARA 3,75% crema, ZYCLARA 3,75% crema | Fundació Clínic per a la Recerca Biomèdica, Meda Pharma | actinic keratosis Queratosis actínica | | | | |
2013-004228-12: PDT vs PDT in combination with 3,75% Imiquimod in patients with actinic keratosis PDT vs PDT in Kombination mit 3,75% Imiquimod bei patienten mit aktinischen Keratosen |
|
|
| Ongoing | 4 | 56 | Europe | Ameluz, Zyclara, EMEA/H/C/002204-N/005, EMEA/H/C/002387, Ameluz, Zyclara, Ameluz, Zyclara | Medizinische Universität Wien, univ. Klinik f. Dermatologie, Medizinische Universität Wien, Univ. Klinik für Dermatologie | non melanoma skin cancer nicht melanozytäre hauttumore | | | | |
2012-005377-31: Trial of treatment and follow-up of vaginal intraepithelial neoplasia (VAIN) Emättimen solumuutosten seuranta- ja hoitotutkimus |
|
|
| Ongoing | 4 | 30 | Europe | Aldara 5% Emuls voide, Aldara 5% Emuls voide | HYKS Naistensairaala, HYKS Naistensairaala | VAIN, vaginal intraepithelial neoplasia emättimen esiastemuutos | | | | |
2016-000746-59: Trial of treatment of vaginal intraepithelial neoplasia (VAIN). |
|
|
| Ongoing | 4 | 60 | Europe | Aldara 5% Emuls voide, Aldara 5% Emuls voide | HYKS Naistensairaala, HYKS Naistensairaala | VAIN, vaginal intraepithelial neoplasia | | | | |
2020-003316-27: Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream Behanlung Aktinischer Keratosen mit Imiquimod 3,75% Créme im frühestmöglichen Stadium |
|
|
| Not yet recruiting | 4 | 50 | Europe | Zyclara 3.75% cream, Cream, zyclara 3.75% cream sachets | Medical University of Graz, Medical University of Graz | Actintic keratosis Aktinische Keratosen, Actinic Keratosis Aktinische Keratosen, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT02889159: Immunologic Profile of Chronically Photodamaged Skin |
|
|
| Recruiting | 4 | 40 | US | Candida albicans antigen, CANDIN, histamine phosphate, HISTATROL, imiquimod 5% cream, ALDARA, Tape Stripping | University of Michigan | Photoaged Skin, Normal Skin | 12/24 | 12/24 | | |
NCT06356012: Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated With Imiquimod |
|
|
| Not yet recruiting | 4 | 96 | NA | Imiquimod, IXIUM, Loop Electrosurgical Excision Procedure, LEEP | Barretos Cancer Hospital, Fundação de Amparo à Pesquisa do Estado de São Paulo, Farmoquimica S.A., Hospital de Cancer de Barretos - Fundacao Pio XII | HSIL, High-Grade Squamous Intraepithelial Lesions, Vaginal Microbiome, Biomarkers | 12/26 | 12/28 | | |
ACTRN12611001083987: A randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma. |
|
|
| Active, not recruiting | 3 | 500 | | | University of Nottingham, Cancer Research UK | low risk superficial basal cell carcinoma, low risk nodular basal cell carcinoma | | | | |
2007-002776-33: Treatment of superficial basal cell carcinoma by three non-invasive modalities: PDT vs. imiquimod vs. 5-fluorouracil |
|
|
| Ongoing | 3 | 300 | Europe | Imiquimod, Efudix, Metvix, EU/1/98/080/001, RVG06292, RVG31130, Imiquimod, Efudix, Metvix creme, Imiquimod, Efudix, Metvix creme | Academic hospital Maastricht | superficial basal cell carcinoma | | | | |
2012-002052-17: Primary Imiquimod Treatment versus Surgery for a precancerous condition of the vulva |
|
|
| Ongoing | 3 | 110 | Europe | not applicable, Aldara 5% cream, Aldara 5% cream | Medizinische Universität Graz, Univ. Frauenklinik, Abteilung für Gynäkologie, FWF, Meduni Graz | Vulvar intraepithelial neoplasia | | | | |
2012-004518-32: Topical Imiquimod Compared with Conization to Treat Cervical Intraepithelial Neoplasia |
|
|
| Ongoing | 3 | 500 | Europe | Aldara, EU/1/98/080/001-002, | Medizinische Universität Wien, Fonds der Österreichischen Nationalbank | In this randomized controlled, multi-center trial we will investigate the non-inferiority of a topical IMQ treatment compared to surgical standard treatment in selected patients diagnosed with CIN 2/3. | | | | |
2016-000712-15: Clinical study to compare two creams with the active substance imiquimod and one cream without active substance for patients with actinic keratosis |
|
|
| Ongoing | 3 | 426 | Europe | Imiquimod 5% cream, Aldara 5% Creme, Cream, Aldara 5% Creme | Dermapharm AG, Dermapharm AG | Actinic keratosis, Actinic keratosis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Active, not recruiting | 3 | 145 | Europe | Imiquimod 5% cream with prior curettage, Aldara, Standard surgical excision | Maastricht University Medical Center | Nodular Basal Cell Carcinoma | 12/17 | 12/22 | | |
ACTRN12615000266561: A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna (LM) when staged surgical excision with 5mm margins is not possible, is refused, or fails. |
|
|
| Active, not recruiting | 3 | 266 | | | Melanoma and Skin Cancer (MASC) Trials, Cancer Australia | Lentigo maligna (LM) | | | | |
ANCHOR, NCT02135419: Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions |
|
|
| Active, not recruiting | 3 | 4446 | US | imiquimod, Aldara, IMQ, R 837, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, Efudex, infrared photocoagulation therapy, infrared coagulation, IRC, thermal ablation therapy, laser therapy, therapy, laser, clinical observation, observation, laboratory biomarker analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas, University of California, San Francisco, University of Arizona | Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection | 08/21 | 03/24 | | |
| Completed | 3 | 126 | RoW | Imiquimod, Aldara, Radiotherapy | Melanoma and Skin Cancer Trials Limited, Melanoma Institute Australia | Lentigo Maligna | 12/21 | 03/23 | | |
NCT04143451: Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients |
|
|
| Recruiting | 3 | 4000 | RoW | Vaxigrip tetra, Fluzone high-dose, Aldara 5% Topical Cream, Aqueous cream BP | The University of Hong Kong | Influenza | 09/22 | 03/23 | | |
NCT02059499: Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions |
|
|
| Completed | 3 | 91 | US | imiquimod, Aldara, IMQ, R 837, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, questionnaire administration, laboratory biomarker analysis | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas | Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection | 12/23 | 04/24 | | |
PRIOH-1, NCT03073967 / 2020-004940-27: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects |
|
|
| Recruiting | 3 | 153 | Europe, Canada, US, RoW | Pritelivir, Investigator's choice, Foscarnet or Cidofovir or Imiquimod | AiCuris Anti-infective Cures AG, Medpace, Inc. | HSV Infection | 01/25 | 04/25 | | |
| Not yet recruiting | 3 | 200 | Europe | Imiquimod 5% cream, Aldara, Placebo cream, Doritin, Fulguration | Medical University Innsbruck | Anogenital Human Papillomavirus Infection, Condyloma Anal | 11/24 | 11/24 | | |
| Not yet recruiting | 3 | 1630 | US | 5% Imiquimod cream, IMQ, Placebo Vehicle Control Cream, Placebo | VA Office of Research and Development | Basal Cell Carcinoma | 01/30 | 01/31 | | |
ACTRN12615001088538: Topical Imiquimod or Diphenylcyclopropenone for the Management of Cutaneous In-transit Melanoma Metastases – A Phase II Single Centre Prospective Randomised Pilot Study |
|
|
| Recruiting | 2 | 30 | | | Professor B Mark Smithers, Princess Alexandra Hospital - Queensland Health | Cutaneous in-transit melanoma metastases | | | | |
2013-000893-32: Skin cancer prevention in people who have had organ transplants by the use of treatment creams to get rid of actinic keratosis skin lesions (cancer precursors)- does this work? |
|
|
| Ongoing | 2 | 120 | Europe | Imiquimod, 5-Fluorouracil, Cream, Aldara, Efudix cream | Queen Mary University of London, National Institute of Health Research | Actinic keratosis (and cutaneous squamous cell carcinoma), Red, scaly skin lesions that may develop into cancerous skin lesions, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2005-001824-35: Non-randomised phase II trial of Sequential Therapy of Imiquimod followed by Vaccination with TA CIN for High Grade VIN |
|
|
| Ongoing | 2 | 30 | Europe | Aldara, TA-CIN, N/A, Imiquimod, Imiquimod | University of Manchester, Central Manchester and Manchester Childrens University Hospitals NHS Trust | VIN3 | | | | |
2006-004327-11: A randomised phase II multi-centre trial of topical treatment in women with vulval intraepithelial neoplasia |
|
|
| Ongoing | 2 | 204 | Europe | Aldara 5% cream, Vistide, Aldara 5% cream, Vistide | Cardiff University | Vulval Intraepithelial Neoplasia grade 3 (VIN 3) | | | | |
2008-004611-35: Phase I/II study: on the toxicity and effects of combining the p53 synthetic long peptides vaccine with either Imiquimod or Interferon-alfa to induce polarized p53-specific immunity in patients treated for colorectal cancer |
|
|
| Ongoing | 2 | 20 | Europe | p53-SLP vaccine, Aldara, PEGintron, Aldara, PEGintron | Leiden University Medical Center | adult both male and femal patients treated for colorectal cancer | | | | |
2010-022502-40: Prospektive, randomisierte, klinische 4-Arm Pilotstudie zur Dosisfin-dung der kombinierten Anwendung von P.L.E.A.S.E. mit 5% topischen Imiquimod versus Standardapplikation von 5% topischem Imiquimod bei aktinischen Keratosen |
|
|
| Ongoing | 2 | 12 | Europe | Imiquimod, Aldara Cream, Aldara Cream | Pantec Biosolution AG | Actinic Keratosis | | | | |
2010-022703-22: Local immunotherapy by the synergism of monobenzone and imiquimod cream (MI) for cutanous metastases in stage III-IV melanoma patients. |
|
|
| Ongoing | 2 | 20 | Europe | monobenzone, monobenzone, Aldara, Aldara | NKI-AVL | patients with cutanous melanoma (stage III-IV) | | | | |
2011-003134-13: ALA-PDT for premalignant vulvar disorders. ALA-PDT voor premaligne vulva aandoeningen. |
|
|
| Ongoing | 2 | 180 | Europe | 5-Aminolevulinic Acid, Aldara 5% cream (Imiquimod), Dermovate, Not applicable, Aldara (Imiquimod), Dermovate cream 0,5 mg/g, Aldara (Imiquimod), Dermovate cream 0,5 mg/g | Erasmus MC, Erasmus MC | Premalignant vulvar disorders (usual type Vulvar Intraepithelial Neoplasia) Premaligna vulvaire aandoeningen (usual type Vulvaire Intraepitheliale Neoplasie) | | | | |
2017-000746-22: Blood vessel changes in regular skin cancer undergoing either electrochemotherapy or conventional topical treatment assessed with optical coherence tomography Ændringer i blodkar i almindelig hudkræft under enten elektrokemoterapi eller konventionel behandling vurderet med optisk kohærens tomografi. |
|
|
| Ongoing | 2 | 75 | Europe | Powder for solution for injection/infusion, Cream, Bleomycin "Baxter", Aldara®, Orifarm A/S, DK, Metvix® | Department of Dermatology, Zealand University Hospital, Roskilde, Department of Dermatology, Zealand University Hospital, Roskilde, LEO fondet | Basal cell carcinoma in adults Basalcellekræft hos voksne, Regular skin cancer also called basal cell carcinoma Almindelig hudkræft, også kaldet basalcellekræft, Diseases [C] - Cancer [C04] | | | | |
2019-002285-12: Keramod Gel vs Aldara for the treatment of actinic keratosis Keramod Gel vs Aldara en el tratamiento de la queratosis actínica |
|
|
| Not yet recruiting | 2 | 68 | Europe | KERAMOD, NA, Gel, Cream, ALDARA | LABORATORIO OJER PHARMA, S.L., LABORATORIO OJER PHARMA, S.L. | ACTINIC QUERATOSIS, also known as solar keratosis, is a skin disease caused by chronic exposure to sunlight. It appears as scaly lesions on the skin as a result of an abnormal growth of the cells in the most outer layer of the epidermis. There may be a single lesion or multiple lesions, and they are usually found on areas of the skin that are regularly exposed to the sun, such as the face, neck, hands, forearms and scalp. QUERATOSIS ACTÍNICA, Conocida también como queratosis solar, La queratosis actínica es un parche grueso y escamoso en la piel, que se desarrolla después de muchos años de exposición al sol. Comúnmente se encuentra en el rostro, cuello, el dorso de las manos, los antebrazos y el cuero cabelludo., ACTINIC QUERATOSIS, also known as solar keratosis, is a skin disease caused by chronic exposure to sunlight. QUERATOSIS ACTÍNICA, Conocida también como queratosis solar, La queratosis actínica es un parche grueso y escamoso en la piel, que se desarrolla después de muchos años de exposición al sol., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2020-005595-35: Local complement activation after dermal inflammatory challenge |
|
|
| Ongoing | 2 | 15 | Europe | Cream, ALDARA 5% cream | Centre for Human Drug Research, Q32bio | Inflammation / Complement activation, Inflammation, Body processes [G] - Immune system processes [G12] | | | | |
2019-003567-21: Anti-inflammatory drugs in a TRL4 and TLR7 topical challenge model |
|
|
| Not yet recruiting | 2 | 60 | Europe | Aldara, Prednisolone solution 0.5 mg/kg, Ointment, Oral solution, Aldara 5% | Centre for Human Drug Research, Centre for Human Drug Research | None, None, Body processes [G] - Immune system processes [G12] | | | | |
2021-005429-26: In vivo immune activation after prolonged TLR-7 inflammatory challenge |
|
|
| Ongoing | 2 | 10 | Europe | Cream, Aldara 5% cream | Centre for Human Drug Research, CHDR | Inflammation / Complement activation, Inflammation, Body processes [G] - Immune system processes [G12] | | | | |
2021-005996-37: Gene and protein expression after treatment of actinic keratosis Gen- og proteinudtryk efter behandling af aktiniske keratoser. |
|
|
| Ongoing | 2 | 60 | Europe | Melatonin, Cream, Tolak, Aldara | Zealand University Hospital, Zealand University Hospital, RepoCeuticals A/S | Actinic keratoses, Solar keratoses, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT02864147: Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) |
|
|
| Completed | 2 | 134 | US | 9-valent HPV vaccine, Imiquimod | Yale University | Cervical Intraepithelial Neoplasia, Cervical Dysplasia | 05/22 | 11/22 | | |
NCT05314127: Efficacy of Tazarotene in Treatment of Verruca Plana |
|
|
| Recruiting | 2 | 80 | RoW | Tazarotene 0.1% Gel,Top, Imiquimod, Fluorouracil Cream, Petrolatum | Zagazig University | Warts Flat | 10/22 | 12/22 | | |
NCT00799110: Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod |
|
|
| Active, not recruiting | 2 | 23 | US | GM-CSF, Dendritic Cell/Tumor Fusion Vaccine, DC/tumor fusion vaccine, imiquimod | Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, National Cancer Institute (NCI) | Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 12/24 | 12/24 | | |
SONIB, NCT03534947: A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma |
|
|
| Recruiting | 2 | 20 | RoW | Sonidegib, LDE225, Odomzo, Imiquimod, Aldara, Surgery, Excision of remnant invasive basal cell carcinoma, Best supportive care | Melanoma Institute Australia | Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified, Skin Cancer, Invasive Carcinoma | 06/24 | 06/24 | | |
| Recruiting | 2 | 48 | Europe | 5Fluorouracil, Imiquimod, Melatonin | Ismail Gögenur | Actinic Keratoses | 02/24 | 12/24 | | |
IDMODVHB, NCT05028322: Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen |
|
|
| Not yet recruiting | 2 | 60 | NA | IMIQUIMOD cream, HEPATITIS B SURFACE ANTIGEN | Central Hospital, Nancy, France | Cirrhosis, Liver, Vaccination Failure, HBV, Vaccine Reaction | 12/24 | 12/24 | | |
2010-020435-40: Phase I/II study of peptide vaccination associated with tumoral immunomodulation with proinflammatory cytokines and imiquimod in patients with advanced metastatic melanoma |
|
|
| Ongoing | 1/2 | 21 | Europe | MAGE-3.A1, NA17.A2 peptide, MAGE-3.A1, NA17.A2, Powder for suspension for injection, Powder for solution for injection, Powder and solvent for solution for injection, Cream, Solution for injection, Proleukine®, Leukine®, Aldara®, IntronA® | Centre du Cancer | metastatic melanoma patients with regional disease (any T; N2c or N3; M0) or with distant metastatic disease ( any T; any N; M1a, M1b or M1c), except uncontrolled brain or CNS metastases, and elevated LDH (superior to 1,5 times the upper normal value) | | | | |
2014-003025-18: Vaccination with peptides (molecules) and other ingredients which stimulate the anticancer immune system in patients with advanced cancers |
|
|
| Ongoing | 1 | 30 | Europe | Human telomerase reverse transcriptase peptides, Aldara 5% cream, Not applicable, Cyclophosphamide 50, Not applicable, Concentrate for solution for injection, Cream, Capsule, hard, Tablet, Aldara 5% cream, Celebrex 100mg and 200 mg capsules | King's College London, Guy's and St Thomas NHS Foundation Trust, Candles, charity, Candles - charity | Advanced malignancies, Cancers which are no longer responding to treatment, Diseases [C] - Cancer [C04] | | | | |
NCT01803152: Dendritic Cell Vaccine for Children and Adults With Sarcoma |
|
|
| Completed | 1 | 19 | US | Dendritic Cells Vaccine, DC Vaccine, Lysate of Tumor, Lysate, Tumor Lysate, Gemcitabine, Gemzar, Imiquimod, Aldara, Leukapheresis, Pheresis | Macarena De La Fuente, MD | Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma | 09/19 | 06/24 | | |
NCT03196180: Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia |
|
|
| Active, not recruiting | 1 | 13 | US | Imiquimod, Aldara, R 837, S 26308, Zyclara, Topical Fluorouracil, Actino-Hermal, Arumel, Carac, Cytosafe, Efudex, Efurix, Fiverocil, Fluoroplex, Flurox, Timazin, Tolak | National Cancer Institute (NCI) | Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2, High Grade Cervical Intraepithelial Neoplasia | 11/20 | 11/24 | | |
NCT03276832: Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma |
|
|
| Active, not recruiting | 1 | 7 | US | Imiquimod, Aldara, R 837, S 26308, Zyclara, Biopsy, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, Nuclear Magnetic Resonance Imaging, NMRI, Structural MRI, sMRI | Mayo Clinic, National Cancer Institute (NCI) | Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | 10/21 | 06/24 | | |
NCT00788164: Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia |
|
|
| Completed | 1 | 75 | US | TA-HPV, pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine, imiquimod | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI) | Cervical Cancer, Precancerous Condition, HPV Disease, Human Papilomavirus | 08/23 | 08/23 | | |
| Active, not recruiting | 1 | 15 | US | Imiquimod 5% Cream | Medical University of South Carolina | Oral Cancer | 06/23 | 09/24 | | |
NCT06305910: CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults |
|
|
| Recruiting | 1 | 24 | US | Treatment with CD200AR-L, Imiquimod, GBM6-AD, Single dose of radiation (300 cGy) | OX2 Therapeutics | Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma | 09/25 | 01/27 | | |
NCT03872947: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 187 | Europe, US | TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD | Toray Industries, Inc | Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 03/25 | 03/25 | | |
NCT03370406: Intralesional 5-Fluorouracil (5FU), Topical Imiquimod Treatment for SCC |
|
|
| Recruiting | 1 | 30 | US | 5-fluorouracil, Adrucil, Tolak, Efudex, Carac, Fluoroplex, PremierPro Rx Fluorouracil, Fluorouracil Novaplus, 5FU, Imiquimod 5% cream, Aldara, Zyclara | Melissa Pugliano-Mauro, National Cancer Institute (NCI) | Carcinoma, Squamous Cell | 08/24 | 09/24 | | |
| Recruiting | 1 | 45 | Europe | GA2, BCG, YF-17D (fractional ID dose), Stamaril, Imiquimod, Aldara, Mock immunization | Leiden University Medical Center | Malaria,Falciparum | 12/24 | 12/24 | | |
NCT01795313: Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod |
|
|
| Recruiting | 1 | 24 | US | HLA-A2 restricted synthetic tumor antigen, Imiquimod, enzyme-linked immunosorbent assay, flow cytometry, immunohistochemistry staining method, laboratory biomarker analysis | James Felker, Solving Kids' Cancer, National Cancer Institute (NCI) | Ependymoma | 12/24 | 12/25 | | |
| Recruiting | 1 | 15 | Europe | Tecentriq 1200 MG in 20 ML Injection, Atezolizumab, H3K27M peptide vaccine, Imiquimod (5%), Aldara | German Cancer Research Center, Johannes Gutenberg University Mainz, Charite University, Berlin, Germany, Roche Pharma AG, German Cancer Aid | Newly Diagnosed H3-mutated Glioma | 03/25 | 03/25 | | |
NCT02600949: Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer |
|
|
| Recruiting | 1 | 150 | US | Imiquimod, Aldara, R 837, S 26308, Zyclara, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Sotigalimab, APX 005, APX 005M, APX-005M, APX005M, CD40 Agonistic Monoclonal Antibody APX005M, EPI-0050, Synthetic Tumor-Associated Peptide Vaccine Therapy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, CT, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MR, MRI Scan, Nuclear Magnetic Resonance Imaging, NMR, NMRI, NMR Imaging | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7 | 05/25 | 05/25 | | |
NCT05838599: Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides |
|
|
| Recruiting | 1 | 25 | US | Imiquimod, Radiation Therapy | Northwestern University | Mycosis Fungoides | 08/25 | 02/26 | | |
NCT04859361: Comparison of Treatment of Cervical Intraepithelial Lesions With Imiquimod or LLETZ |
|
|
| Active, not recruiting | N/A | 104 | Europe | Aldara 5% Topical Cream, Zyclara, imiquimod, LLETZ, LEEP | University Medical Centre Maribor | Intraepithelial Neoplasia, Cervical | 04/20 | 09/23 | | |
NCT05146895: A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts |
|
|
| Recruiting | N/A | 60 | RoW | Imiquimod treatment, Local Hyperthermia at 44℃ | First Hospital of China Medical University | Human Papilloma Virus | 06/22 | 06/22 | | |
NCT04809662: Comparing Immune Responses to Topical Imiquimod |
|
|
| Active, not recruiting | N/A | 110 | US | Imiquimod, Aldara, Zyclara | University of California, Davis | Actinic Keratoses | 12/22 | 12/22 | | |
ChiCTR2000030180: A randomized controlled study of imiquimod combined with CO2 laser in the treatment of vaginal intraepithelial neoplasia |
|
|
| Not yet recruiting | N/A | 60 | | primary CO2 laser treatment combined with imiquimod maintenance treatment ;CO2 laser repeat treatment | Shanghai Tongji hospital; Shanghai Tongji Hospital, Clinical Research Plan of SHDC | Vaginal intraepithelial neoplasia | | | | |
NCT05315024: Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children |
|
|
| Not yet recruiting | N/A | 72 | NA | Fluarix Tetra, Imiquimod cream | The University of Hong Kong | Influenza | 09/23 | 10/23 | | |
| Not yet recruiting | N/A | 36 | NA | Azithromycin, Biopsy, Skin inflammation model | Medical University of Vienna | Skin Infection | 01/26 | 07/26 | | |
REDT-BCC, NCT06252857: Real-world Evaluation of Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma |
|
|
| Recruiting | N/A | 142 | Europe | Imiquimod Topical, Surgical Excision | Maastricht University Medical Center | Basal Cell Carcinoma | 04/26 | 04/26 | | |
NCT06411106: Deep Phenotyping of Cutaneous Lupus Erythematosus |
|
|
| Recruiting | N/A | 40 | Europe | IMIQUIMOD cream 50mg/g, Aldara | Centre for Human Drug Research, Netherlands | Cutaneous Lupus Erythematosus | 09/25 | 09/25 | | |
| Recruiting | N/A | 410 | Europe | Imiquimod, Aldara, 3x vaginal swab for microbiome analysis, Expectative management, 2x vaginal swab for microbiome analysis | Catharina Ziekenhuis Eindhoven, ZonMw: The Netherlands Organisation for Health Research and Development, Stichting Olijf: Dutch patient association for women with gynaecological cancer, Leids Universitair Medisch Centrum: Department of Medical Oncology and Department of Pathology, Maastricht Universitair Medisch Centrum: Department of Gynaecology and Department of Pathology, Erasmus Medisch Centrum: Department of Gynaecology, Radboud Medisch Centrum: Department of Gynaecology | Cervical High Grade Squamous Intraepithelial Lesion, Cervical Intraepithelial Neoplasia Grade 2/3, CIN 2/3, Cervical Intraepithelial Neoplasia | 12/24 | 12/26 | | |
ACTRN12613000207718: Dermoscopy for monitoring therapeutic response to non-surgical treatments of in-situ squamous cell carcinoma. |
|
|
| Not yet recruiting | N/A | 100 | | | Aristotle University of Thessaloniki, Aristotle University of Thessaloniki | Actinic Keratosis, Bowen's Disease | | | | |